Results 71 to 80 of about 517,509 (243)
Chilling Complications: A Case of COVID-Associated Cold Autoimmune Hemolytic Anemia (AIHA) [PDF]
Cold Agglutinin disease (CAD) also known as Cold Autoimmune Hemolytic Anemia (AIHA) is a form of autoimmune hemolytic anemia wherein cold agglutinins (IgM autoantibodies against red blood cell (RBC) antigens) bind during cold temperatures causing ...
Patel, Kishan B., Coz, Julian
core +1 more source
Abstract Autoimmune haemolytic anaemia is a rare immune‐mediated disorder leading to accelerated red cell destruction and anaemia. There is considerable clinical heterogeneity, with some patients barely requiring intervention, while others experience fulminant haemolysis and experience mortality rates as high as 30% with severe anaemia and end‐organ ...
Philip Choi +9 more
wiley +1 more source
Concurrent Atypical Hemolytic Uremic Syndrome and Autoimmune Hemolytic Anemia: a case report
Background: Atypical hemolytic uremic syndrome (aHUS) is a life-threatening and scarce disorder characterized by acute renal failure and disease, non-immune microangiopathic hemolytic anemia and thrombocytopenia, leading to end-stage renal failure or ...
Sayed Yousef Mojtahedi +1 more
doaj
Iron overload is commonly seen in the context of hematological diseases in patients who require frequent transfusions. On the other hand, an association between autoimmune hemolytic anemia complicating chronic lymphocytic leukemia and iron overload is ...
Mohammad Ali, Mohamed A. Yassin
doaj +1 more source
Autoimmune hemolytic anemia is a relatively uncommon pediatric clinical condition. As such, the evaluation and management of these cases can be challenging for even the most seasoned pediatrician. In this review, the 3 major forms of autoimmune hemolytic
Blackall, Douglas, Dolatshahi, Lily
core +1 more source
ABSTRACT Glycated albumin (GA), the product of nonenzymatic glycation of serum albumin, reflects the mean glucose levels over the preceding approximately 2 weeks, bridging the gap between daily self‐monitoring of blood glucose and the roughly 3‐month window covered by glycated hemoglobin (HbA1c) measurement.
Masakazu Aihara, Naoto Kubota
wiley +1 more source
Management of autoimmune hemolytic anemia
Abstract Autoimmune hemolytic anemia (AIHA) is caused by premature erythrocyte destruction mediated by autoantibodies (auto-Ab) with or without complement activation. The most frequent form (60%-70% of cases) is warm AIHA (wAIHA), driven by immunoglobulin G auto-Ab that react at body temperature. Cold agglutinin disease (CAD, 20%-25%)
Barcellini, Wilma, Fattizzo, Bruno
openaire +2 more sources
Immune‐related adverse events with mogamulizumab in cutaneous T‐cell lymphoma: A multicentre study
In a nationwide multicentre study of 403 patients with cutaneous T‐cell lymphoma treated with mogamulizumab, non‐MAR immune‐related adverse events were reported in 8.4% of patients across responding centres. These events were diverse, sometimes severe or persistent, and could occur late during mogamulizumab treatment.
David Neubauer +28 more
wiley +1 more source
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma +5 more
wiley +2 more sources
Autoimmune hemolytic anemia (AIHA) is characterized by shortening of red blood cell (RBC) survival and the presence of autoantibodies directed against autologous RBCs.
Behzad Nazel Khosroshahi +5 more
doaj

